
Ionis Pharmaceuticals, Inc. IONS
Analyst Consensus
Price Objectif
Analyst historical
Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
---|---|---|---|---|---|
Justin Kim | Oppenheimer | 68.94 $ | 90 $ | 21.06 % | 08/10/2025 |
Gena Wang | Barclays | 61.36 $ | 82 $ | 20.64 % | 23/09/2025 |
Gary Nachman | Raymond James | 61.36 $ | 75 $ | 13.64 % | 22/09/2025 |
Kostas Biliouris | BMO Capital | 60.49 $ | 70 $ | 9.51 % | 03/09/2025 |
Gena Wang | Barclays | 57.49 $ | 78 $ | 20.51 % | 02/09/2025 |
Michael Ulz | Morgan Stanley | 57.49 $ | 71 $ | 13.51 % | 02/09/2025 |
Mitchell Kapoor | H.C. Wainwright | 57.49 $ | 95 $ | 37.51 % | 02/09/2025 |
Yanan Zhu | Wells Fargo | 42.69 $ | 82 $ | 39.31 % | 22/08/2025 |
Debjit Chattopadhyay | Guggenheim | 37.8 $ | 65 $ | 27.20 % | 09/10/2024 |
Kostas Biliouris | BMO Capital | 51.32 $ | 60 $ | 8.68 % | 02/08/2024 |
Mani Foroohar | Leerink Partners | 51.86 $ | 62 $ | 10.14 % | 24/07/2024 |
Akash Tewari | Jefferies | 50.61 $ | 77 $ | 26.39 % | 22/07/2024 |
Salveen Richter | Goldman Sachs | 50.61 $ | 33 $ | -17.61 % | 22/07/2024 |
Akash Tewari | Jefferies | 49.84 $ | 75 $ | 25.16 % | 16/07/2024 |
Paul Matteis | Stifel Nicolaus | 47.7 $ | 53 $ | 5.30 % | 27/06/2024 |
Luca Issi | RBC Capital | 40.63 $ | 70 $ | 29.37 % | 17/06/2024 |
William Pickering | Tudor Pickering | 41.12 $ | 44 $ | 2.88 % | 14/06/2024 |
Kostas Biliouris | BMO Capital | 36.84 $ | 67 $ | 30.16 % | 17/05/2024 |
Do Kim | Piper Sandler | 37.56 $ | 55 $ | 17.44 % | 21/06/2022 |
Joseph Stringer | Needham | 32.49 $ | 60 $ | 27.51 % | 24/02/2022 |
Luca Issi | RBC Capital | 32.49 $ | 67 $ | 34.51 % | 24/02/2022 |
Jason Gerberry | Bank of America Securities | 31.51 $ | 30 $ | -1.51 % | 01/02/2022 |
Gena Wang | Barclays | 34.63 $ | 33 $ | -1.63 % | 04/11/2021 |
Yale Jen | Laidlaw | 30.25 $ | 68 $ | 37.75 % | 18/10/2021 |
Esther Rajavelu | UBS | 36.24 $ | 37.5 $ | 1.26 % | 10/05/2021 |
Kevin DeGeeter | Oppenheimer | 39.89 $ | 63 $ | 23.11 % | 05/05/2021 |